Mira Katan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The CONVINCE trial of the anti-inflammatory drug colchicine missed its primary endpoint, but secondary analyses suggested benefit.

Mira katanPeter kellyEuropean stroke organization conferenceUniversity college dublin school of medicineUniversity hospital of baselUniversity college dublin schoolNovel targetUniversity hospital